Evidence map›Paper›PMID 38377192›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2024

Diverse cytomegalovirus US11 antagonism and MHC-A evasion strategies reveal a tit-for-tat coevolutionary arms race in hominids.

Cosima Zimmermann, Gabrielle M Watson, Liane Bauersfeld, Richard Berry, Barbara Ciblis, Huan Lan, Carolin Gerke, Valerie Oberhardt, Jonas Fuchs, Maike Hofmann and 5 more

Open access · hybridAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 3 countries.

Cosima Zimmermann *Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, 79104 Freiburg, Germany.ORCID 0000-0003-2956-1410
Gabrielle M Watson *Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Monash Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.
Liane BauersfeldInstitute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, 79104 Freiburg, Germany.
Richard BerryInfection and Immunity Program and Department of Biochemistry and Molecular Biology, Monash Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.ORCID 0000-0001-7043-0469
Barbara CiblisInstitute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, 79104 Freiburg, Germany.
Huan LanInstitute for Chemistry and Biochemistry, Freie Universität Berlin, 14195 Berlin, Germany.ORCID 0009-0004-4790-2498
Carolin GerkeInstitute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, 79104 Freiburg, Germany.
Valerie OberhardtDepartment of Medicine II, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, 79104 Freiburg, Germany.
Jonas FuchsInstitute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, 79104 Freiburg, Germany.ORCID 0000-0003-1974-212X
Maike HofmannDepartment of Medicine II, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, 79104 Freiburg, Germany.ORCID 0000-0001-8410-8833
Christian FreundInstitute for Chemistry and Biochemistry, Freie Universität Berlin, 14195 Berlin, Germany.ORCID 0000-0001-7416-8226
Jamie RossjohnInfection and Immunity Program and Department of Biochemistry and Molecular Biology, Monash Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.ORCID 0000-0002-2020-7522
Frank MomburgAntigen Presentation and T/NK Cell Activation Group, German Cancer Research Center, Clinical Cooperation Unit Applied Tumor Immunity, German Cancer Research Center, 69120 Heidelberg, Germany.
Hartmut HengelInstitute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, 79104 Freiburg, Germany.ORCID 0000-0002-3482-816X
Anne HaleniusInstitute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, 79104 Freiburg, Germany.ORCID 0000-0001-6335-1017
University of Freiburg · DEAustralian Regenerative Medicine Institute · AUFreie Universität Berlin · DEGerman Cancer Research Center · DEUniversity Hospital of Wales · GB

Funding

Deutsche Forschungsgemeinschaft (DFG) 278001972 ( TRR 186)Deutsche Forschungsgemeinschaft (DFG) FR1325/20-1Deutsche Forschungsgemeinschaft (DFG) HA 6035/2-2Deutsche Forschungsgemeinschaft (DFG) HE 2526/9-1
6 · The paper itself

Abstract

Recurrent, ancient arms races between viruses and hosts have shaped both host immunological defense strategies as well as viral countermeasures. One such battle is waged by the glycoprotein US11 encoded by the persisting human cytomegalovirus. US11 mediates degradation of major histocompatibility class I (MHC-I) molecules to prevent CD8+ T-cell activation. Here, we studied the consequences of the arms race between US11 and primate MHC-A proteins, leading us to uncover a tit-for-tat coevolution and its impact on MHC-A diversification. We found that US11 spurred MHC-A adaptation to evade viral antagonism: In an ancestor of great apes, the MHC-A A2 lineage acquired a Pro184Ala mutation, which confers resistance against the ancestral US11 targeting strategy. In response, US11 deployed a unique low-complexity region (LCR), which exploits the MHC-I peptide loading complex to target the MHC-A2 peptide-binding groove. In addition, the global spread of the human HLA-A*02 allelic family prompted US11 to employ a superior LCR strategy with an optimally fitting peptide mimetic that specifically antagonizes HLA-A*02. Thus, despite cytomegaloviruses low pathogenic potential, the increasing commitment of US11 to MHC-A has significantly promoted diversification of MHC-A in hominids.

Indexed as

Histocompatibility Antigens Class IHominidaeAnimalsCell LineCytomegalovirusHistocompatibility AntigensHLA-A AntigensHumansPeptidesViral ProteinsHistocompatibility AntigensHistocompatibility Antigens Class IHLA-A AntigensPeptidesViral ProteinscoevolutioncytomegalovirusHLA-AMHC class Itapasin

Identifiers

PMID38377192
PMCPMC10907249
OpenAlexW4391952835

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.